Simulation of surface engineering for ultra shallow junction formation of PMOS for the 90nm CMOS technology node and beyond

Abstract-Since the junctions in the most advanced CMOS devices are thinner and thinner, the influence of the surface of silicon is thus becoming significant on dopant diffusion. In this paper, based on experimental data, a methodology for calibration is proposed, taking this effect of surface into account. SIMS profiles are accurately fitted by simulation using a simple model of recombination of interstitials; the phenomenon of POED is well reproduced and validated by TCAD 1D simulations. Then, the impact of POED on the PMOS performances is quantified by anticipation with 2D TCAD simulations

The sex-specific factor SOA controls dosage compensation in <i>Anopheles</i> mosquitos

The Anopheles mosquito is one of thousands of species in which sex differences play a central role in their biology, as only females need a blood meal in order to produce eggs. Sex differentiation is regulated by sex chromosomes, but their presence creates a dosage imbalance between males (XY) and females (XX). Dosage compensation (DC) can re-equilibrate the expression of sex-chromosomal genes, but because DC mechanisms have only been fully characterized in a few model organisms, key questions about its evolutionary diversity and functional necessity remain unresolved 1. Here we report the discovery of a previously uncharacterized gene (SOA, for sex chromosome activation) as a master regulator of DC in the malaria mosquito Anopheles gambiae. Sex-specific alternative splicing prevents functional SOA protein expression in females. The male isoform encodes a DNA-binding protein that binds the promoters of active X chromosomal genes. Expressing male SOA is sufficient to induce DC in female cells. Male mosquitoes lacking SOA or female mosquitos ectopically expressing the male isoform exhibit X chromosome misregulation, which is compatible with viability but causes developmental delay. Thus, our molecular analysis of the first DC master regulator in a non-model organism elucidates the evolutionary steps leading to the establishment of a chromosome-specific fine-tuning mechanism

Etat des lieux des secours à personne en Limousin et des arrêts cadio-repispiratoires extra-hospitaliers d'août 2010 à janvier 2011

LIMOGES-BU Médecine pharmacie (870852108) / SudocSudocFranceF

PDP 4PS : Periodic-Delayed Protocol for Partitioned Systems

International audienc

Ants of French Guiana: 16S rRNA sequence dataset

This dataset represents a reference library of DNA sequences for ants from French Guiana. A total of 3931 new sequences from the 16S rRNA gene has been generated. The reference library covers 344 species distributed in 57 genera. Overall, 3920 sequences have been assigned at the species level and 11 at the genus level. All these sequences were submitted to DDBJ/EMBL/GenBank databases in the Bioproject: PRJNA779056: 16S French Guiana Ants (Hymenoptera: Formicidae), sequence identifier KFFS00000000

Ants of French Guiana: a DNA barcode dataset

This dataset represents a DNA barcode reference library for ants from French Guiana. A total of 3931 new sequences from 16S rRNA gene has been generated. The reference library covers 344 species distributed in 57 genera. 3920 sequences are assigned at the species level and 11 at the genus level. All these sequences were submitted to DDBJ/EMBL/GenBank databases in the Bioproject: PRJNA779056: 16S French Guiana Ants (Hymenoptera: Formicidae), sequence identifier KFFS00000000

Enhanced neutralization escape to therapeutic monoclonal antibodies by SARS-CoV-2 omicron sub-lineages

Summary: The landscape of SARS-CoV-2 variants dramatically diversified with the simultaneous appearance of multiple subvariants originating from BA.2, BA.4, and BA.5 Omicron sub-lineages. They harbor a specific set of mutations in the spike that can make them more evasive to therapeutic monoclonal antibodies. In this study, we compared the neutralizing potential of monoclonal antibodies against the Omicron BA.2.75.2, BQ.1, BQ.1.1, and XBB variants, with a pre-Omicron Delta variant as a reference. Sotrovimab retains some activity against BA.2.75.2, BQ.1, and XBB as it did against BA.2/BA.5, but is less active against BQ.1.1. Within the Evusheld/AZD7442 cocktail, Cilgavimab lost all activity against all subvariants studied, resulting in loss of Evusheld activity. Finally, Bebtelovimab, while still active against BA.2.75, also lost all neutralizing activity against BQ.1, BQ.1.1, and XBB variants